Universe Pharmaceuticals Inc.
Price Action
Technical Summary
CONSOLIDATINGUniverse Pharmaceuticals Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is leading (RS Rating: 95), indicating clear outperformance against the broad market. Earnings contraction of 100% provides fundamental context to the price action. However, price is extended 83% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $4.01 | +54.89% | ABOVE |
| 50 SMA | $3.39 | +83.28% | ABOVE |
| 100 SMA | $3.12 | +99.07% | ABOVE |
| 150 SMA | $3.45 | +80.01% | ABOVE |
| 200 SMA | $3.75 | +65.50% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is UPC in an uptrend right now?
UPC has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is UPC overbought or oversold?
UPC's RSI (14) is 55. The stock is in neutral territory, neither overbought nor oversold.
Is UPC outperforming the market?
UPC has a Relative Strength (RS) Rating of 95 out of 99. Yes, UPC is a market leader, outperforming 95% of all stocks over the past 12 months.
Where is UPC in its 52-week range?
UPC is trading at $6.21, which is 35% of its 52-week high ($17.96) and 26% above its 52-week low ($2.00).
How volatile is UPC?
UPC has a Beta of 0.66 and 52-week volatility of 142%. It's less volatile than the S&P 500 - generally more stable.